UNCOVERED: 5 - Caught on Camera

Irish parents ‘breaking down and crying’ as children denied life changing Cystic Fibrosis medication

Sarah O’Keeffe found out that her son would not be getting the medication that would improve his life

Dublin Live · Jun 8, 2022

Thousands sign petition demanding 35 kids with Cystic Fibrosis be given life-saving drug Kaftrio

'The lives of our children are at stake here, and we need to have this drug'

Irish Mirror · Jun 2, 2022

What 4 Analyst Ratings Have To Say About Vertex

Analysts have provided the following ratings for Vertex (NASDAQ:VERX) within the last quarter:

Benzinga · May 23, 2022

Why Vertex Pharmaceuticals Shares Are Falling

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower by 3.42% to $263.88 during Monday’s pre-market session after the company announced VX-880 Phase 1/2 has been placed on clinical hold by the FDA due to “a determination that there is insufficient information to support do

Benzinga · May 2, 2022

This Obscure Stock Has Outperformed Tech And EV Giants

Vertex Energy Inc (NASDAQ: VTNR) has an average trading volume of over 2 million, so it is no slouch of a stock in terms of interest. 

Benzinga · Apr 29, 2022

Vertex Touts Positive Data From Mid-Stage Study Of Its Non-Opioid Pain Drug

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released positive results from two Phase 2 post-operative trials for its non-opioid program, VX-548.  One trial looked at patients who had just received a bunionectomy (Correcting the deformity of toes & foot), the other in patients who received abdominoplasty (tummy tuck). Vertex said that within 48 hours of surgery,…

Benzinga · Mar 31, 2022

Well played: Cause for celebration as cystic fibrosis drug added to the PBS

Without PBS subsidy, around 1,900 Australians would be up for more than $250,000 a year to access the CF drug.

Newcastle Herald · Mar 29, 2022

What's Going On With Vertex Energy Shares Today?

Vertex Energy Inc (NASDAQ: VTNR) is trading higher on above-average volume Thursday as oil prices gain following the collapse of Russia-Ukraine ceasefire talks. 

Benzinga · Mar 10, 2022

Vertex Clocks 12% Revenue Growth In Q4 Backed By ARR, NRR Momentum; Issues FY22 Guidance Above Consensus

Vertex Inc (NASDAQ:VERX) reported fourth-quarter FY21 revenue growth of 12.2% year-on-year to $111.7 million, beating the consensus of $109.2 million. Software subscription revenues rose 11.1% Y/Y to $93.3 million, and Cloud revenues increased 38.9% Y/Y to $34.7 million. Drivers: Annual Recurring Revenue rose 17% Y/Y to $370.2 million. The Average Annual Revenue per customer…

Benzinga · Mar 9, 2022

Vertex: Q4 Earnings Insights

  Vertex (NASDAQ:VERX) reported its Q4 earnings results on Wednesday, March 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 9, 2022